High-dose N-acetyl cysteine (NAC) is associated with reduced levels of glial fibrillary acidic protein (GFAP) in patients with progressive multiple sclerosis, according to findings from a Phase 2 clinical study. Researchers presented the data, pointing to a potential biomarker shift in neurodegenerative disease tracking.
Understanding GFAP Levels in Progressive Multiple Sclerosis
Glial fibrillary acidic protein serves as a primary biomarker for astrocyte activation and central nervous system injury. In progressive forms of multiple sclerosis, elevated GFAP blood levels often correlate with ongoing disease activity and physical disability worsening. According to clinical data discussed in neurology research updates, finding interventions that lower or stabilize these biomarker levels remains a central goal for altering the trajectory of progressive MS.
Phase 2 Study Design and Findings
The Phase 2 trial evaluated the impact of high-dose N-acetyl cysteine on biological markers in participants diagnosed with progressive multiple sclerosis. Investigators tracked changes in biochemical indicators over the course of the intervention period. According to study metrics covered by NeurologyLive, patients receiving the high-dose regimen demonstrated a measurable decrease in serum GFAP concentrations compared to baseline measurements.
N-acetyl cysteine acts as a precursor to glutathione, a major endogenous antioxidant. Researchers are examining whether its antioxidant and anti-inflammatory properties can mitigate chronic oxidative stress within the central nervous system. While the Phase 2 trial provides initial signals regarding biomarker modulation, larger confirmatory trials are required to establish clear clinical efficacy and functional benefits for patients.
Implications for Future MS Research
The association between high-dose NAC and diminished GFAP levels opens new avenues for monitoring therapeutic responses in neurodegeneration. Clinical investigators note that utilizing blood-based biomarkers like GFAP allows for more rapid evaluation of experimental therapies before waiting for visible changes on standard magnetic resonance imaging scans. Future phases of research will test these dosing strategies across broader patient cohorts to confirm safety and long-term impact.
Related reading